Sofosbuvir vs. Combination of pegylated interferon and ribavirin; How much shall pay for Iranian patients?

Hepatitis Monthly

Volumn 14, Issue 11, 2014, Pages

  Pourhoseingholi, Mohamad Amin ^a   Ashtari, Sara ^a   Alavian, Seyed Moayed ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Middle East Liver Diseases Research Center   (Iran)

Author keywords

Cost; Hepatitis C; Peginterferon; Sofosbuvir; Therapy

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR;

CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMIC ASPECT; EDITORIAL; HEALTH CARE COST; HEPATITIS; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; IRANIAN PEOPLE; NONHUMAN; QUALITY OF LIFE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRAL PHENOMENA AND FUNCTIONS;

EID: 84912142412     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.25540     Document Type: Editorial

References (10)

1. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in IR IRAN. Gastro Hepat. 2009;3(1):5–14.
2. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-efectiveness analysis. Am J Gastroenterol. 2006;101(9):2076–89.
3. Ashtari S, Vahedi M, Pourhoseingholi MA, Karkhane M, Kimiia Z, Pourhoseingholi A, et al. Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon. 2013;13(5).
4. Alavian SM, Mirmomen S, Lankarani KB, Adibi P, Merat S. What is the optimal treatment? Hepat Mon. 2004;4(4):5.
5. Sargolzaee Aval F, Behnaz N, Raoufy MR, Alavian SM. Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artifcial neural network. Hepat Mon. 2014;14(6).
6. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavi-rin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100–7.
7. Alavian SM. Sofosbuvir has come out of the magic box. Hepat Mon. 2013;13(12).
8. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al. Cost-efectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2014;59(5):1692–705.
9. Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-efectiveness analysis of sofosbuvir plus peginterferon/ ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014;40(6):657–75.
10. Leleu H, Blachier M, Rosa I. Cost-efectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2014.